JeanMarie Guenot is Transforming How We Fight Cancer

JeanMarie Guenot is a woman of great knowledge and drive and has worked with companies in the public’s eye as well as privately, building and rebuilding existing companies. For over 20 years she has been a business executive with a Ph.D. in pharmaceutical and biotechnology, working in almost every major therapeutic areas. She is who is behind the scenes creating answers and solutions to the unknown.

Guenot conducts research about illnesses, including previous patients who have been treated and present patients being treated and analyzes the results, constantly adjusting and modifying treatments. JeanMarie Guenot began her journey in 1987 at the University of California where she gained her Ph.D and she trained in physical and medicinal chemistry. She also gained her MBA at the Wharton School at the University of Pennsylvania. Guenot’s employment began as a Principal Scientist and business adviser for Hoffman-La Roche in Basel and Shanghai at a company called Roche, a biotechnology company that is focused on treating patients as best as possible in a personalized manner.

Read more: Maverick Therapeutics and Takeda Announce Five-year Collaboration to Advance T-Cell Engagement Therapies

JeanMarie has held several titles including Vice President, managing partner and Founder. In 2009 she founded a company called SKS Ocular. It is a private ophthalmology company, focusing on the eyes with illnesses such as glaucoma, macular degeneration and ocular inflammation and finds treatments in order to transform them into something better in order to help preserve and improve the vision of suffering patients. She left SKS Ocular just three years later and is currently the President and CEO of Amphivena Therapeutics according to Crunchbase. At Amphivena Therapeutics there is a focus on blood cancers and using the patients own immune system to destroy these cancers by destroying the tumor cells and the chemical compounds found in the blood that create the tumor cells. This is called antibody therapy and it is a “first in class bi functional antibody therapy to address blood cancer indication with high unmet medical needs.

Learn more about Jeanmarie Guenot: http://www.guenotllc.com/Biography.html